Microsatellite instability cancer+1
Not recruitingStudy Comparing MK-1308A and Pembrolizumab for Patients with Advanced Colorectal Cancer with High Microsatellite Instability or Mismatch Repair Deficiency
Study Comparing MK-1308A and Pembrolizumab for Patients with Advanced Colorectal Cancer with High Microsatellite Instability or Mismatch Repair Deficiency
- Disease:Microsatellite instability cancerColorectal cancer stage IV
- Substances:MK-4830Pembrolizumab+2
France- Participants:18–64 years · 65+ years
- Substances:MK-4830
- Sponsor:Merck Sharp & Dohme LLC











